CLAIMS

1. Use of hyaluronic acid in the manufacture of a composition for treating hair loss in a patient in need thereof, wherein the composition is to be administered to the skin of the patient, and wherein the composition comprises hyaluronic acid in a concentration of 50 mcg/mL to 250 mcg/mL.

2. The use of claim 1, wherein the hyaluronic acid comprises an average molecular weight in a range of 4,000 Da to 10,000 Da or in a range of 20 KDa to 1350 KDa.

3. The use of claim 1 or 2, wherein the hyaluronic acid is cross-linked and optionally wherein the cross-linked hyaluronic acid density is 20% or greater.

4. The use of any one of claims 1 to 3, wherein the hyaluronic acid is present in a concentration of 100 mcg/mL to 250 mcg/mL.

5. The use of any one of claims 1 to 3, wherein the hyaluronic acid has a concentration of 100 ug/mL or less.

6. The use of any one of claims 1 to 5, wherein the composition is to be injected into the skin.

7. The use of claim 6, wherein the composition is to be injected into a dermal layer of the skin.

8. The use of claim 7, wherein the composition is to be injected for 400 microns to 2 mm deep into the skin.

9. The use of any one of claims 6 to 8, wherein the composition is to be administered in a plurality of injections in an amount of 400 injections/cm^2 skin to 650 injections/cm^2 skin.

10. The use of any one of claims 1 to 9, wherein the composition is to be further applied with iontophoresis to the skin.

11. The use of any one of claims 1 to 10, wherein the composition is to be further applied with electroporation to the skin.

12. The use of any one of claims 1 to 11, wherein the composition is to be further applied with laser ablation to the skin.

13. The use of any one of claims 1 to 12, wherein the composition is to be further applied with radiofrequency thermal ablation to the skin.

14. The use of any one of claims 1 to 13, wherein the composition is to be further applied with a needle to the skin.

15. The use of claim 14, wherein the needle is a microneedle device.

16. The use of any one of claims 1 to 15, wherein the composition further comprises a CD44-binding ligand.

17. The use of claim 16, wherein the CD44-binding ligand is osteopontin.